ClinicalTrials.gg
CompletedNCT01365091Updated May 8, 2015Results posted

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

A Phase 1 interventional study of Saxagliptin/metformin fixed-dose combination (FDC) and Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in Brazil. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
39th of 74
112 · median 138
Started
2011
with 2 others
Phase 1
14 of 74
none open now
Registered
33rd of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment, is one of 3 that started in 2011, is one of 14 in phase 1, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with saxagliptin, 5-mg and metformin, 500-mg XR tablets administered together in both the fasted and fed states. In addition, to demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin XR, 1000-mg, FDC tablet with saxagliptin, 5-mg and metformin, 1000-mg XR tablets administered together in both the fasted and fed states.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy men and women
  • women of who are using acceptable method of
  • Women who are not pregnant or nursing
  • (BMI) of 18 to 29.9 kg/m\^2, inclusive. BMI=weight(kg)/height(m)\^2.

Key Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • History of gastrointestinal (GI) disease
  • Major surgery within 4 weeks of study drug administration
  • Any GI surgery that could impact study drug absorption
  • Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within the 6 months of study drug administration.
  • Blood transfusion within 3 months of study drug administration for women and within 2 months for men
  • Inability to be venipunctured and/or tolerate venous access
  • Current smoker or recent (within 1 month) history of regular tobacco use
  • Recent (within 6 months of study drug administration) drug or alcohol abuse
  • Participation in a bioequivalence study within the last 6 months of study drug administration
  • Estimated of \<80 mL/min using Cockcroft-Gault formula
  • History of allergy to drug class or related compounds
  • History of allergy to metformin or other similar acting agents
  • History of any significant drug allergy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Arm 1: Treatments A,B/B,A

    Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days. Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).

    Drug: Saxagliptin/metformin fixed-dose combination (FDC) · Drug: Saxagliptin · Drug: Metformin extended-release (XR)

  • Experimental
    Arm 2: Treatments C,D/D,C

    Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days. Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).

    Drug: Saxagliptin/metformin fixed-dose combination (FDC) · Drug: Saxagliptin · Drug: Metformin extended-release (XR)

  • Experimental
    Arm 3: Treatments E, F/F,E

    Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days. Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).

    Drug: Saxagliptin · Drug: Saxagliptin/Metformin FDC · Drug: Metformin

  • Experimental
    Arm 4: Treatments G,H/H,G

    Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days. Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).

    Drug: Saxagliptin · Drug: Saxagliptin/Metformin FDC · Drug: Metformin

Interventions

  • DrugSaxagliptin/metformin fixed-dose combination (FDC)

    Drug pages: Saxagliptin · Metformin

    Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day

    Also known as: Onglyza/Glucophage extended release (XR)

  • Tablet, oral, 5 mg, once on Day 1 only, 1 day

    Also known as: Onglyza

  • Tablet, oral, 500 mg, once on Day 1 only, 1 day

    Also known as: Glifage XR

  • DrugSaxagliptin/Metformin FDC

    Drug pages: Saxagliptin · Metformin

    Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day

    Also known as: Onglyza/Glucophage XR

  • Tablet, oral, 1000 mg, once on Day 1 only, 1 day

    Also known as: Glifage XR

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets

    Time frame: Days 1, 2, and 3 of Periods 1 and 2

  2. AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets

    AUC=Area under the concentration-time curve

    Time frame: Days 1, 2, and 3 of Periods 1 and 2

  3. AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets

    AUC=Area Under the Concentration-time Curve

    Time frame: Days 1, 2, and 3 of Periods 1 and 2

Secondary outcomes

  1. Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)

    SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1

07

Results

Posted Aug 19, 2013

Participant flow

Period 1
Participant flow — Period 1
MilestoneArm 1: Treatments A/B, B/AArm 2: Treatments C/D, D/CArm 3:Treatments E/ F, F/EArm 4: Treatments G/ H, H/G
Started28282828
Completed26262525
Not completed2233
Withdrew: Adverse event1023
Withdrew: Positive test result for drugs of abuse1000
Withdrew: No longer met study criteria0100
Withdrew: Withdrawal by subject0100
Withdrew: Personal reasons0010
Period 2
Participant flow — Period 2
MilestoneArm 1: Treatments A/B, B/AArm 2: Treatments C/D, D/CArm 3:Treatments E/ F, F/EArm 4: Treatments G/ H, H/G
Started26262525
Completed25262425
Not completed1010
Withdrew: Withdrawal by subject1000
Withdrew: Adverse event0010

Outcome measures

PrimaryMaximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
Time frame:
Days 1, 2, and 3 of Periods 1 and 2
Reported as:
Mean · μg/mL
Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
μg/mLSax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, FastedSax, 5 mg/Met 500 mg vs FDC to Individual Tablets, FedSax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, FastedSax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed
Metformin Cmax (individual tablet)713 ± 176654 ± 1181177 ± 3991077 ± 139
Metformin Cmax (FDC)678 ± 167577 ± 951139 ± 3251091 ± 214
Saxagliptin Cmax (individual tablet)29274 ± 1020928339 ± 733930914 ± 796531319 ± 6270
Saxagliptin Cmax (FDC)31372 ± 1136728140 ± 831133549 ± 781329545 ± 6006
5-OH Saxagliptin Cmax (individual tablets)54709 ± 1681652628 ± 1285056444 ± 1473155177 ± 13751
5-OH Saxagliptin Cmax (FDC)56413 ± 1577511316 ± 4540459878 ± 1595954521 ± 12319
Statistical analysis
  • Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 95.204 · 90% CI 87.618 to 103.446Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 107.606 · 90% CI 96.552 to 119.924Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted · Geometric mean ratio: 104.373 · 90% CI 96.504 to 112.883Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B= FDC (test value)
  • Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 88.188 · 90% CI 82.368 to 94.419Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 98.168 · 90% CI 92.263 to 104.451Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 95.023 · 90% CI 91.470 to 98.714Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 97.601 · 90% CI 15.55 to 99Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 110.656 · 90% CI 102.416 to 119.559Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 106.264 · 90% CI 99.826 to 113.117Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 100.028 · 90% CI 95.164 to 105.139Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 93.644 · 95% CI 89.055 to 98.470Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
PrimaryAUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets

AUC=Area under the concentration-time curve

Time frame:
Days 1, 2, and 3 of Periods 1 and 2
Reported as:
Mean · pg*h/mL
AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
pg*h/mLSax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC FastingSax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC FedSax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC FastingSax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed
Metformin AUC(0-T) (individual tablets)5816 ± 18595071 ± 8218174 ± 23949628 ± 3270
Metformin AUC(0-T) (FDC)5386 ± 18964701 ± 10288500 ± 27138936 ± 2696
Saxagliptin AUC(0-T) (individual tablets)106070 ± 26733110285 ± 22139102913 ± 22067124536 ± 24794
Saxagliptin AUC(0-T) (FDC)103865 ± 31088109345 ± 2394799215 ± 20146127232 ± 28709
5-OH Saxagliptin AUC(0-T) (individual tablets)320743 ± 68176305354 ± 53254324163 ± 593589628 ± 3270
5-OH Saxagliptin AUC(0-T) (FDC)331332 ± 67491292515 ± 45404323039 ± 560318936 ± 2696
Statistical analysis
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting · ANCOVA · Geometric mean ratio: 91.508 · 90% CI 82.596 to 101.380Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting · ANCOVA · Geometric mean ratio: 97.437 · 90% CI 93.889 to 101.119Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting · ANCOVA · Geometric mean ratio: 96.770 · 90% CI 93.350 to 100.316Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed · ANCOVA · Geometric mean ratio: 91.585 · 90% CI 85.56 to 98.035Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed · ANCOVA · Geometric mean ratio: 98.529 · 90% CI 96.028 to 101.095Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed · ANCOVA · Geometric mean ratio: 96.239 · 90% CI 93.286 to 99.286Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting · ANCOVA · Geometric mean ratio: 102.994 · 90% CI 96.956 to 109.407Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting · ANCOVA · Geometric mean ratio: 97.135 · 95% CI 93.778 to 100.613Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting · ANCOVA · Geometric mean ratio: 100.01 · 90% CI 96.512 to 103.648Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed · ANCOVA · Geometric mean ratio: 92.953 · 90% CI 85.502 to 101.053Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed · ANCOVA · Geometric mean ratio: 101.281 · 95% CI 98.494 to 104.147Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed · ANCOVA · Geometric mean ratio: 100.111 · 90% CI 97.367 to 102.932Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
SecondaryNumber of Participants With Death as Outcome and Serious Adverse Events (SAEs)

SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1
Reported as:
Number · Participants
Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)
ParticipantsArm 1: Treatments A,B/B,AArm 2: Treatments C,D/D,CArm 3: Treatments E,F/ F,EArm 4: Treatments G,H/H,G
Deaths0000
SAEs0000
PrimaryAUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets

AUC=Area Under the Concentration-time Curve

Time frame:
Days 1, 2, and 3 of Periods 1 and 2
Reported as:
Mean · ng*h/mL
AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
ng*h/mLSax, 5 mg/Met 500 mg XR FDC to Individual Tablets, FastedSax, 5 mg/Met 500 mg XR FDC to Individual Tablets, FedSax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, FastedSax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed
Metformin AUC (0-inf) (individual tablets)5877 ± 18585127 ± 8168338 ± 24149731 ± 3277
Metformin AUC (0-inf) (FDC)5443 ± 19054754 ± 10378618 ± 27269054 ± 2684
Saxagliptin AUC (0-inf) (individual tablets)107425 ± 26828111677 ± 22315104293 ± 22149125820 ± 24856
Saxagliptin AUC (0-inf) (FDC)105248 ± 31314110705 ± 24091100620 ± 20264128602 ± 28729
5-OH Saxagliptin AUC (0-inf) (individual tablets)337345 ± 67941310983 ± 53447330247 ± 59863332495 ± 62192
5-OH Saxagliptin AUC (0-inf) (FDC)326501 ± 68475298037 ± 45636329085 ± 56298332869 ± 59469
Statistical analysis
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 91.494 · 90% CI 82.697 to 101.226Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value).
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 97.477 · 90% CI 93.955 to 101.132Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 96.760 · 90% CI 93.393 to 100.247Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value).
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 91.548 · 90% CI 85.573 to 97.939Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 98.535 · 95% CI 96.044 to 101.090Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 96.258 · 95% CI 93.319 to 99.290Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 102.383 · 95% CI 96.589 to 108.525Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 97.187 · 90% CI 93.832 to 100.662Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted · ANCOVA · Geometric mean ratio: 100.015 · 95% CI 96.560 to 103.594Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted vs Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 93.219 · 90% CI 85.835 to 101.238
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 101.346 · 90% CI 98.574 to 104.196Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)
  • Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed · ANCOVA · Geometric mean ratio: 100.056 · 90% CI 97.324 to 102.864Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)

Adverse events

Collected over From screening through Day 1 to within 30 days of drug discontinuation on Day 1. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saxagliptin, 5 mg/Metformin XR, 1000 mg Fasting—0/28 (0%)7/28 (25%)
Saxagliptin, 5 mg/Metformin XR, 1000 mg Fed—0/28 (0%)13/26 (50%)
Saxagliptin, 5 mg/Metformin XR, 500 mg Fasting—0/28 (0%)10/27 (37%)
Saxagliptin, 5 mg/Metformin XR, 500 mg Fed—0/28 (0%)6/26 (23.1%)
Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fasting—0/28 (0%)8/25 (32%)
Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fed—0/28 (0%)4/27 (14.8%)
Saxagliptin, 5 mg/Metformin, 500 mg FDC Fasting—0/28 (0%)8/28 (28.6%)
Saxagliptin, 5 mg/Metformin, 500 mg FDC Fed—0/28 (0%)14/28 (50%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSaxagliptin, 5 mg/Metformin XR, 1000 mg FastingSaxagliptin, 5 mg/Metformin XR, 1000 mg FedSaxagliptin, 5 mg/Metformin XR, 500 mg FastingSaxagliptin, 5 mg/Metformin XR, 500 mg FedSaxagliptin, 5 mg/Metformin, 1000 mg FDC FastingSaxagliptin, 5 mg/Metformin, 1000 mg FDC FedSaxagliptin, 5 mg/Metformin, 500 mg FDC FastingSaxagliptin, 5 mg/Metformin, 500 mg FDC Fed
HeadacheNervous system disorders2/283/2610/271/264/252/277/284/28
Blood creatinine abnormalInvestigations0/280/260/272/260/250/270/286/28
AnaemiaBlood and lymphatic system disorders0/281/261/271/263/250/270/281/28
HypertensionVascular disorders1/283/260/271/260/251/272/281/28
Red blood cell abnormalityBlood and lymphatic system disorders0/283/260/270/260/250/270/280/28
VomitingGastrointestinal disorders3/280/260/270/260/250/270/280/28
White blood cell disorderBlood and lymphatic system disorders1/282/260/270/261/250/270/280/28
Alanine aminotransferase abnormalInvestigations0/282/260/270/260/250/270/280/28
FlatulenceGastrointestinal disorders0/281/260/272/261/250/271/281/28
DysgeusiaNervous system disorders1/280/262/270/260/250/272/280/28

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm 1: Treatments A/B, B/AArm 2: Treatments C/D, D/CArm 3:Treatments E/ F, F/EArm 4: Treatments G/ H, H/GTotal
<=18 years00000
Between 18 and 55 years28282828112
>=55 years00000
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm 1: Treatments A/B, B/AArm 2: Treatments C/D, D/CArm 3:Treatments E/ F, F/EArm 4: Treatments G/ H, H/GTotal
Both genders28282828112
08

Study locations

1 site
  • Local Institution
    Campinas, Sao Paulo 13073, Brazil
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2011
First posted
Jun 3, 2011
Start
Jun 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Aug 19, 2013
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01365091
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Jun 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Aug 19, 2013
Last update
May 8, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion